



FY2021 Q1 Financial Results

July 30, 2021 TOPCON CORPORATION

Director and Managing Executive Officer, CFO General Manger of Accounting & Finance Div.

Haruhiko Akiyama









Contents

FY2021 Q1 Financial Results

- I. FY2021 Q1 Financial Results
- II. FY2021 Full Year Plan
- III. Topics
- IV. Summary
- V. Appendix





I . FY2021 Q1 Financial Results

I - 1. FY2021 Q1 Financial Results


I - 2. Overview of Each Business





FY2021 Q1 Overview

OPCON



FY2021 Q1 Financial Results

Record-high sales, operating income, and ordinary income for Q1

(unit: million yen)

					· , , , , , , , , , , , , , , , , , , ,
		FY2020		FY2021	
		Q1 Actual	Q1 Actual	YoY	%
Net Sales		24,493	38,898	14,404	+59%
Gross Profit (Gross Profit Ratio)		11,680 (47.7%)	20,331 (52.3%)	8,650	+74%
SGA		14,003	16,872	2,869	
Operating Inco		-2,322 (-9.5%)	3,458 (8.9%)	5,781	
Non-Operating In (Expenses)	come	-721	-250	470	
Ordinary Income		-3,043	3,208	6,252	
Extraordinary In	icome	-31	0	31	
Income Before Incom Minority Interests	ne Taxes and	-3,074	3,208	6,283	
Net Income		-2,482	1,823	4,305	
Exchange Rate (Average)	USD	¥107.74	¥110.00	¥2.26	
	EUR	¥118.94	¥131.78	¥12.84	
4 -0-0-0	_			_	




FY2021 Q1 Financial Results by Business

Significant increase in sales and operating income for all business segments

					(unit: million yen)
		FY2020		FY2021	
		Q1 Actual	Q1 Actual	YoY	%
	Positioning	14,416	22,645	8,228	+57%
	Smart Infrastructure	6,331	8,700	2,369	+37%
Not Color	Eye Care	6,343	11,398	5,055	+80%
Net Sales	Others	229	275	45	+20%
	Elimination	-2,827	-4,122	-1,295	
	Total	24,493	38,898	14,404	+59%
	Positioning	553 (3.8%)	3,061 (13.5%)	2,508	+453%
• 4	Smart Infrastructure	235 (3.7%)	1,287 (14.8%)	1,051	+446%
Operating Income (Operating	Eye Care	-1,904 (-30.0%)	233 (2.1%)	2,138	Turns profitable
Income Ratio)	Others	-138 (-60.2%)	-89 (-32.5%)	48	-
	Elimination	-1,069	-1,034	35	
	Total	-2,322 (-9.5%)	3,458 (8.9%)	5,781	_



FY2021 Q1 Operating Income YoY Breakdown



I . FY2021 Q1 **Financial Results**

I - 1. FY2021 Q1 Financial Results

I - 2. Overview of Each Business





Record high sales and operating income for Q1

(unit: million ye	

	FY2020		FY2021	(unit. million yen)
	Q1 Actual	Q1 Actual	YoY	%
Net Sales	14,416	22,645	8,228	+57%
Operating Income (Operating Income Ratio)	553 (3.8%)	3,061 (13.5%)	2,508	+453%
Exchange USD Rate (Average) EUR	¥107.74 ¥118.94	¥110.00 ¥131.78	¥2.26 ¥12.84	

Review of FY2021 Q1 Financial Results

Overall

- Significant increase in sales and operating income on strong demands mainly in the U.S. and Europe

IT Construction


- Continuing strong sales for the aftermarket, substantially surpassed the pre-COVID-19 level
- Significant sales growth for OEM, recover to pre-COVID-19 level

IT Agriculture

- Continuing strong sales for the aftermarket, substantially surpassed the pre-COVID-19 level
- Significant sales growth for OEM, recover to pre-COVID-19 level

Surveying and laser products

 Buoyant housing construction market in the U.S. and Europe continues due to increase of relocation demands to suburbs amid COVID-19







Overview of Each Business

Smart Infrastructure

Record high sales and operating income for Q1

(unit: million ye	

	FY2020		FY2021	(unit. million yen)
	Q1 Actual	Q1 Actual	YoY	%
Net Sales	6,331	8,700	2,369	+37%
Operating Incom (Operating Income Rat	235 (3.7%)	1,287 (14.8%)	1,051	+446%
Exchange USI Rate (Average) EUI	¥107.74 ¥118.94	¥110.00 ¥131.78	¥2.26 ¥12.84	

Review of FY2021 Q1 Financial Results

Overall


- Growing sales driven by solid domestic sales
- Stagnation in Southeast Asia continues

Japan

- Construction: Strong sales for surveying instruments and machine guidance system for small-sized excavators
- IT Agriculture: Despite temporary backlash of increased demand due to subsidies of last year, we see solid progress in sales thanks to persistent demand for labor saving technology

The U.S. and Europe

- Strong sales continues for surveying instruments and laser products







Overview of Each Business



■ Significant sales increase, turning profitable

(unit: million yen)

	FY2020	FY2021		
	Q1 Actual	Q1 Actual	YoY	%
Net Sales	6,343	11,398	5,055	+80%
Operating Income (Operating Income Ratio)	-1,904 (-30.0%)	233 (2.1%)	2,138	Turns profitable
Exchange USD	¥107.74	¥110.00	¥2.26	
Rate (Average) EUR	¥118.94	¥131.78	¥12.84	

Review of FY2021 Q1 Financial Results

Overall

- Continuing strong sales driven by the U.S., Europe, and China

Screening business


Demands from major optical chain stores have recovered
 Sales of 3D OCT continue to grow

Tele-optometry

- Solid demands continue for remote eye-exam

China

 Continuing strong sales by capturing strong appetite for capital investment and growing demands for Al Screening





II. FY2021 Full Year Plan





FY2021 Full Year Plan

Outlook

■ Outlook for the macro environment

- Thanks to vigorous demands for housing and civil infrastructure investment and high level of grain prices, demands will continue to expand in construction and agricultural sectors mainly in the U.S. and Europe
- On the other hand, the outlook remains uncertain due to rising material prices and logistics costs, the impact of semiconductor shortages on production and subsequent longer lead-time of shipping/sales, and rising concerns over the spread of new variants of COVID-19 mainly in Southeast Asia

Outlook for each Business

Positioning

- Strong trend will continue in the U.S. and Europe construction markets while automation needs are increasing due to the shortage of construction labor force
- Farmers' strong appetite for capital investment will continue thanks to high level of grain prices

Smart Infrastructure

- Favorable trend will continue due to National resilience program and numbers of i-Construction works are expected to grow
- In terms of IT agriculture, the demands reactionary decline due to termination of the subsidies, however, uptrend of adoption of automation technologies will continue thanks to persistent labor-saving needs
- Southeast Asia will continue to suffer from prolonged COVID-19 pandemic and the timing of recovery remains uncertain

Eye Care

- Demands for screening business in the U.S. and Europe is expected to expand steadily
- There is certain growth prospects in China while the economic outlook is somewhat uncertain
- Southeast Asia will continue to suffer from prolonged COVID-19 pandemic and the timing of recovery remains uncertain





FY2021 Full Year Plan

■ No change from the initial plan

(unit: million yen)

		FY2020	FY202	1
		Full Year Actual	Full Year Plan	YoY (%)
Net Sales		137,247	149,000	+9%
Operating (Operating Ind		6,593 (4.8%)	10,000 (6.7%)	+52%
Ordinary I	ncome	5,587	8,000	+43%
Net Incom	е	2,376	5,000	+110%
ROE		3.6%	7%	
Dividends		¥10	¥20	
Payout Ra	ntio	44%	42%	
Exchange Rate (Average)	USD EUR	¥106.17 ¥123.73	* ¥108.00 ¥128.00	

^{*} Q2 onward





FY2021 Full Year Plan

(unit: million yen)

		FY2020	FY2021
		Full Year Actual	Full Year YoY Plan (%)
	Positioning	71,416	78,000 +9%
	Smart Infrastructure	33,982	36,000 +6%
Not Color	Eye Care	44,251	50,000 +13%
Net Sales	Others	1,165	1,000 -14%
	Elimination	-13,568	-16,000
	Total	137,247	149,000 +9%
	Positioning	6,064 (8.5%)	7,000 (9.0%) +15%
Operating	Smart Infrastructure	4,972 (14.6%)	5,000 (13.9%) +1%
Income	Eye Care	122 (0.3%)	2,500 (5.0%) +1,949%
(Operating Income Ratio)	Others	-536 (-46.0%)	-300 (-30.0%)
	Elimination	-4,028	-4,200
	Total	6,593 (4.8%)	10,000 (6.7%) +52%



III. Topics



Further Expansion of Screening Business in China



Strengthening collaboration with Omron Healthcare to grow Screening Business in China

(News released on June 8, 2021)

https://www.topcon.co.jp/news/20210608-29503.html

*only available in Japanese

Areas of collaboration:

Promotion of Screening Business

for lifestyle-related diseases





OMRON develops screening facilities

Metabolic Management Centers (MMCs)

A facility in which related data of diabetic patients from medical experts, pharmaceutical manufacturers and medical ICT companies is gathered and managed. Appropriate medical examinations including complications are available.

(760 sites as of March 2021)



Fundus Camera TRC-NW400

One-touch operation with a full automatic functionality

Social background

Expanding demands for medical screening tests in China, due to an increase in patients with lifestyle-related diseases (hypertension, diabetes, etc.)

Our initiatives

- Provides NW400 to facilities operated by Omron (for diabetic screening tests)
- Strengthen sales activities to other health screening centers as well





Enhancement of product portfolio




Topcon acquires VISIA Imaging S.r.I, ophthalmic medical device manufacturer in Italy

(News released on July 7, 2021) https://www.topcon.co.jp/en/news/20210707-29645.html

The Italian company specializes in the design, development, and manufacturing of anterior segment (cornea, crystalline lens, etc.) examination hardware and software

Reinforcing Topcon's comprehensive strength as an ophthalmic diagnostic device manufacturer



Objectives

- Enhancing product portfolio
- Strengthening global development and production structure for Eye Care Business





Topcon selected by METI as "DX Stocks 2021" for two consecutive years

Solving the societal challenges within healthcare, agriculture, and infrastructure through DX solutions is highly acclaimed!

(News released on June 7, 2021)

https://www.topcon.co.jp/news/20210607-29484.html *only available in Japanese




Out of approx. 3,700 listed companies in Japan,

28 with the highest overall rating were selected as DX stocks

Our overall rating

(Source: METI presentation material)



METI presentation material (only in Japanese)




IV. Summary





Summary

No change from the initial plan





Topcon for Human Life 医・食・住






V. Appendix







Financial Results (Quarterly)




Financial Results and Plan (Annually)



Sales by region










Capital Expenditure and R&D / Forex Sensitivity



Forex Sensitivity (impact by ¥1 change)

USD: Operating Income ¥0.15B - ¥0.2B

EUR: Operating Income ¥0.07B - ¥0.1B









Cautionary Note regarding Forward-Looking Statements

These materials contain forward-looking statements, including projections of future operating performance. Such statements are based on management's best judgment, given the materials available to them at the time these statements are made.

However, please be aware that actual performance may differ from projected figures owing to unexpected changes in the economic environment in which we operate, as well as to market fluctuations.

The original disclosure in Japanese was released on July 30, 2021 at 15:00(UTC+9)

Inquiries:

Corporate Communication Div.

Corporate Communication Dept.

TOPCON CORPORATION

Tel: +81-3-3558-2532

E-mail: investor_info@topcon.co.jp

URL: https://global.topcon.com/invest/



